Milbank LLP advised Sartorius AG in an auction process on the execution of an agreement to acquire three businesses of Danaher’s Life Science portfolio with locations in Europe, USA and China in a mixed share/asset deal. The cash purchase price amounts to approximately $750 million. The acquisition is subject to customary closing conditions, inter alia, antitrust clearance, as well as the successful acquisition of the GE Biopharma business by Danaher and related regulatory approvals.
Sartorius Group is a leading international partner of biopharmaceutical research and the industry. In fiscal 2018, the company earned sales revenue of some €1,57 billion with around 8,800 employees at approximately 60 manufacturing and sales sites globally.
Danaher is a global science and technology company with more than 20 operating companies in the fields of health care, environmental and applied end-markets. In 2018, Danaher earned sales revenue of approximately $20 billion with around 71,000 employees globally.
The Milbank team led by the partners Michael Bernhardt and Alexander Rinne advised the buyer comprehensively on the corporate and antitrust law aspects of the transaction.
Advisor to Buyer: Milbank LLP
Michael Bernhardt (lead, Corporate, Frankfurt), Roland Hlawaty, Scott Golenbock (both Corporate, New York), Alexander Rinne (Antitrust, Munich), Christoph Rothenfusser (Corporate, Munich), Fiona Schaeffer (Antitrust, New York), Dominik Waldvogel, Sarah-Maria Resch, Andreas Rief (all Corporate, Frankfurt), Monica Arduini, Reed Homan, Andi Hasaj (all Corporate, New York), Moritz Lichtenegger, Susanne Schricker (both Antitrust, Munich), Sean Heiden (Regulatory, Washington, D.C.), Nina Marot (Technology, London).
Sartorius Inhouse: Jens Michael Artelt (lead, Head of Legal Affairs & Compliance)